Glycemic variability is an independent predictive factor for development of hepatic fibrosis in nonalcoholic fatty liver disease

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Hashiba, Motoi ^a   Ono, Masafumi ^a   Hyogo, Hideyuki ^b   Ikeda, Yukio ^c   Masuda, Kosei ^a   Yoshioka, Reiko ^a   Ishikawa, Yoichi ^a   Nagata, Yuri ^a   Munekage, Kensuke ^a   Ochi, Tsunehiro ^a   Hirose, Akira ^a   Nozaki Fujimura, Yasuko ^a   Noguchi, Shuhei ^a   Okamoto, Nobuto ^a   Chayama, Kazuaki ^b   Suganuma, Narufumi ^a   Saibara, Toshiji ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c National Hospital Organization   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN;

ADULT; ARTICLE; BLOOD GLUCOSE MONITORING; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; INSULIN RELEASE; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; ORAL GLUCOSE TOLERANCE TEST; PREDICTION;

ADULT; AGED; BLOOD GLUCOSE; DEOXYGLUCOSE; DISEASE PROGRESSION; FATTY LIVER; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INSULIN; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS;

EID: 84892429113     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0076161     Document Type: Article

References (37)

1. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, et al (1999) Nonalcoholic fatty liver diseases: a spectrum of clinical and pathological severity. Gastroenterology 116: 1413-1419.
2. Rafiq N, Bai C, Fang Y, Srishord M, McCullough A, et al (2009) Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 7: 234-238.
3. Ono M, Saibara T (2006) Clinical features of nonalcoholic steatohepatitis in Japan: evidence from literature. J Gastroenterol 41: 725-732.
4. Reddy SK, Steel JL, Chen HW, DeMateo DJ, Cardinal J, et al (2012) Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. HEPATOLOGY 55: 1809-1819.
5. Chitturi S, Abeygunasekera S, Farrell GC, Holmes-Walker J, Hui JM, et al (2002) NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome. HEPATOLOGY 35: 373-379.
6. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, et al (2003) Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. HEPATOLOGY 37: 917-923.
7. Angulo P (2002) Nonalcoholic fatty liver disease. N. Engl. J. Med. 18: 1221-1231.
8. Neuschwander-Tetri BA, Clark JM, Bass NM, Van Natta ML, Unalp-Arida A, et al (2010) Clinical, laboratory and histological associations in adults with nonalcoholic fatty liver disease. HEPATOLOGY 52: 913-924.
9. Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, et al (2008) Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. HEPATOLOGY 48: 792-798.
10. Hossain N, Afendy A, Stepanova M, Nader F, Srishord M, et al (2009) Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 7: 1224-1229.
11. Sonsuz A, Basaranoglu M, Bilir M, Turk H, Akin P (2002) Hyperinsulinemia in nondiabetic, both obese and nonobese patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 97: 495.
12. Angulo P (2007) Obesity and nonalcoholic fatty liver disease. Nutr. Rev. 65: S57-63.
13. Ceriello A, Esposito K, Piconi L, Ihnat MA, Thorpe JE, et al (2008) Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 57: 1349-1354.
14. Node K, Inoue T (2009) Postprandial hyperglycemia as an etiological factor in vascular failure. Cardiovasc Diabetol. 8: 23.
15. Monnier L, Mas E, Ginet C, Michel F, Villon L, et al (2006) Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 295: 1681-1687.
16. Hirose A, Ono M, Saibara T, Nozaki Y, Masuda K, et al (2007) Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis. HEPATOLOGY. 45: 1375-1381.
17. Fujii H, Kawada N (2012) Inflammation and fibrogenesis in steatohepatitis. J Gastroenterol. 47: 215-225.
18. Klonoff DC (2005) Continuous glucose monitoring: roadmap for 21st century diabetes therapy. Diabetes Care. 28: 1231-1239.
19. Bialasiewicz P, Pawlowski M, Nowak D, Loba J, Czupryniak L (2009) Decreasing concentration of interstitial glucose in REM sleep in subjects with normal glucose tolerance. Diabetic Medicine. 26: 339-344.
20. Whalan DJ (1975) The ethics and morality of clinical trials in man. Med. J. Aust. 19: 491-494.
21. Brunt EM (2001) Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 21: 3-16.
22. Koschinsky T, Heinemann L (2001) Sensors for glucose monitoring: technical and clinical aspects. Diabetes/Metabolism Research and Reviews 17: 113-123.
23. Yoneda M, Fujii H, Sumida Y, Hyogo H, Itoh Y, et al (2011) Japan Study Group of Nonalcoholic Fatty Liver Disease. Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroenterol. 46: 1300-1306.
24. Kimura Y, Hyogo H, Ishitobi T, Nabeshima Y, Arihiro K, et al (2011) Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus. J Gastroenterol Hepatol. 26: 517-522.
25. Manchanayake J, Chitturi S, Nolan C, Farrell GC (2011) Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol. 26: 510-516.
26. Ota T, Takamura T, Kurita S, Matsuzawa N, Kita Y, et al (2007) Insulin resistance accelerates a dietary rat model of nonalcoholic steatohepatitis. Gastroenterology. 132: 282-293.
27. Starley BQ, Calcagno CJ, Harrison SA (2010) Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection. HEPATOLOGY. 51: 1820-1832.
28. Kaji K, Yoshiji H, Kitade M, Ikenaka Y, Noguchi R, et al (2008) Impact of insulin resistance on the progression of chronic liver diseases. Int J Mol Med. 22: 801-808.
29. Kilpatrick ES, Rigby AS, Atkin SL (2006) The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care. 29: 1486-1490.
30. Hirsch IB, Brownlee M (2005) Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications. 19: 178-181.
31. Kilpatrick ES, Rigby AS, Atkin SL (2010) For debate. Glucose variability and diabetes complication risk: we need to know the answer. Diabet Med. 27: 868-871.
32. Watada H, Azuma K, Kawamori R (2007) Glucose fluctuation on the progression of diabetic macroangiopathy-new findings from monocyte adhesion to endothelial cells. Diabetes Res Clin Pract. 77 Suppl 1: S58-61.
33. Jin WL, Azuma K, Mita T, Goto H, Kanazawa A, et al (2011) Repetitive hypoglycaemia increases serum adrenaline and induces monocyte adhesion to the endothelium in rat thoracic aorta. Diabetologia. 54: 1921-1929.
34. Monnier L, Colette C (2008) Glycemic Variability. Should we and can we prevent it? Diabetes Care. 31, suppl 2: S150-154.
35. Ceriello A, Inta MA (2010) Glycaemic variability: A new therapeutic challenge in diabetes and the critical care setting. Diabetes UK. Diabetic Medicine. 27: 862-867.
36. Egi M, Bellomo R, Stachowski E, French CJ, Hart G (2006) Variability of blood glucose concentration and short-term mortality in critically ill patients. Anesthesiology. 195: 244-252.
37. Pisarchik AN, Pochepen ON, Pisarchyk LA (2012) Increasing blood glucose variability is a precursor of sepsis and mortality in burned patients. PLoS One. 7: e46582.